Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus

Lupus

Volumn 18, Issue 5, 2009, Pages 407-412

  Agarwal, Sangita ^a   Harper, J ^b   Kiely, P D W ^c  

^a GUY S HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Anti ENA antibodies; Disease activity; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; CELL NUCLEUS ANTIGEN; EXTRACTABLE NUCLEAR ANTIGEN ANTIBODY; LA ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 63749113764     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308097784     Document Type: Article

References (19)

1. Tan EM Cohen AS Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
2. Koffler D Schur PH Kunkel HG. Immunological studies concerning the nephritis of systemic lupus erythematosus. J Exp Med 1967; 126: 607-624.
3. Lopez-Longo FJ Monteagudo I Gonzalez CM Grau R Carreño L. Systemic lupus erythematosus: Clinical expression and anti-Ro/SSA response in patients with and without lesions of subacute cutaneous lupus erythematosus. Lupus 1997; 6: 32-39.
4. Oshiro AC Derbes SJ Stopa AR Gedalia A. Anti-Ro/SS-A and anti-La/SS-B antibodies associated with cardiac involvement in childhood systemic lupus erythematosus. Ann Rheum Dis 1997; 56: 272-274.
5. Spronk PE Limburg PC Kallenberg CG. Serological markers of disease activity in systemic lupus erythematosus. Lupus 1995; 4: 86-94.
6. Swaak AJ Groenwold J Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986; 45: 359-366.
7. Walz LeBlanc. BA, Gladman, DD, Urowitz, MB. Serologically active clinically quiescent systemic lupus erythematosus-predictors of clinical flares. J Rheumatol 1994; 21: 2239-2241.
8. Tseng CE Buyon JP Kim M et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 3623-3632.
9. Wahren M Tengner P Gunnarsson I et al. Ro/SS-A and La/SS-B antibody level variation in patients with Sjögren's Syndrome and systemic lupus erythematosus. J Autoimmun 1998; 11: 29-38.
10. Praprotnik S Bozic B Kveder T Rozman B. Fluctuation of anti-Ro/SS-A antibody levels in patients with systemic lupus erythematosus and Sjögren's Syndrome: A prospective study. Clin Exp Rheumatol 1999; 17: 63-68.
11. Derksen RH Meilof JF. Anti-Ro/SS-A and anti-La/SS-B autoantibody levels in relation to systemic lupus erythematosus disease activity and congenital heart block. A longitudinal study comprising two consecutive pregnancies in a patient with systemic lupus erythematosus. Arthritis Rheum 1992; 35: 953-959.
12. Yashuma M Takasaki Y Matsumoto K Kodama A Hashimoto H Hirose S. Clinical significance of IgG anti-Sm antibodies in patients with SLE. J Rheumatol 1990; 17: 469-475.
13. Ter Borg EJ Horst G Limburg PC van Venrooij WJ Kallenberg CG. Changes in levels of antibodies against the 70 kDa and a polypeptides of the U1RNP complex in relation to exacerbations of systemic lupus erythematosus. J Rheumatol 1991; 18: 363-367.
14. Bombardier C Gladman DD Urowitz MB Caron D Chang CH. Derivation of SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
15. Francoeur AM. Anti-SM and anti-U1-RNP lupus antibody fine specificities. J Clin Immunol 1989; 9: 256-263.
16. Petri M Genovese M Engle E Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991; 34: 937-944.
17. Stegeman CA. Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant 2002; 17: 2077-2080.
18. Cambridge G Leandro MJ Teodorescu M et al. B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and anti-microbial antibody profiles. Arthritis Rheum 2006; 54: 3612-3622.
19. Ho A Magder L Barr S Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2342-2349.